Cabozantinib S-malate
Tier B — Position earlyCabozantinib S-malate · all drugs expiring in 2029 →
Targets：VEGFR1, VEGFR2, VEGFR3, KIT, Trk-B, TYRO3, ROS, AXL, RET, TIE2, c-Met, FLT3, MerTK
Brand：Cometriq, Cabometyx
Indications (approved)：Neuroendocrine tumour, Pancreatic neuroendocrine tumour, Renal cell carcinoma, Hepatocellular carcinoma, Thyroid cancer, Neuroendocrine carcinoma
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| CABO-001 | 1131-62-0Available | 1-(3,4-dimethoxyphenyl)ethan-1-one |
| CABO-002 | 4101-32-0Available | 1-(4,5-dimethoxy-2-nitrophenyl)ethanone |
| CABO-003 | 4101-30-8Available | 1-(2-amino-4,5-dimethoxyphenyl)ethanone |
| CABO-004 | 109-94-4Available | ethyl formate |
| CABO-005 | 13425-93-9Available | 6,7-dimethoxyquinolin-4-ol |
| CABO-006 | 849217-54-5Available | 6,7-dimethoxyquinolin-4-yl trifluoromethanesulfonate |
| CABO-007 | 849217-60-3Available | N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide |
| CABO-008 | 598-10-7Available | cyclopropane-1,1-dicarboxylic acid |
| CABO-009 | 371-40-4Available | 4-fluoroaniline |
| CABO-010 | 849217-48-7Available | methyl 1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylate |
| CABO-011 | 123-30-8Available | 4-aminophenol |
| Code | CAS No. | Intermediate |
|---|---|---|
| CABO-009 | 371-40-4Available | 4-fluoroaniline |
| CABO-011 | 123-30-8Available | 4-aminophenol |
| CABO-012 | 35654-56-9Available | 4-chloro-6,7-dimethoxyquinoline |
| CABO-017 | 1559-02-0Available | diethyl cyclopropane-1,1-dicarboxylate |
| CABO-018 | 3697-66-3Available | 1-(ethoxycarbonyl)cyclopropane-1-carboxylic acid |
| CABO-019 | 1584696-72-9Available | ethyl 1-((4-hydroxyphenyl)carbamoyl)cyclopropane-1-carboxylate |
| CABO-020 | 1584696-80-9Available | ethyl 1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate |
| CABO-021 | 849217-77-2Available | 1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| CABO-004 | 109-94-4Available | ethyl formate |
| CABO-005 | 13425-93-9Available | 6,7-dimethoxyquinolin-4-ol |
| CABO-012 | 35654-56-9Available | 4-chloro-6,7-dimethoxyquinoline |
| CABO-013 | 100-02-7Available | 4-nitrophenol |
| CABO-014 | 190728-24-6Available | 6,7-dimethoxy-4-(4-nitrophenoxy)quinoline |
| CABO-015 | 190728-25-7Available | 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline |
| CABO-016 | 1219937-98-0Available | 1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid |
Frequently asked questions
What are the approved indications of Cabozantinib S-malate?
Approved indications include: Neuroendocrine tumour, Pancreatic neuroendocrine tumour, Renal cell carcinoma, Hepatocellular carcinoma, Thyroid cancer, Neuroendocrine carcinoma.
When does the Cabozantinib S-malate patent expire?
Based on public sources, the Cabozantinib S-malate patent expires in 2029.
How many synthesis routes are recorded for Cabozantinib S-malate?
3 synthesis routes are recorded; the shortest is 5 steps with 5.0 kg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Cabozantinib S-malate intermediates?
21 intermediate CAS of Cabozantinib S-malate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Cabozantinib S-malate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29